Andrea Apolo, M.D.
Head, Bladder Cancer Section, Genitourinary Malignancies Branch, National Cancer Institute
Dr. Apolo is a Lasker Clinical Research Scholar, Tenure-Track Investigator, and Chief of theSection of the Genitourinary Malignancies Branch of the National Cancer Institute. She received her M.D. from Albert Einstein College of Medicine in New York and completed an internal medicine residency at New York-Presbyterian Hospital/Weill Cornell Medical Center, followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center. She then joined the Medical Oncology Branch of the National Cancer Institute with the charge of developing a translational program. She holds board certifications for internal medicine and medical oncology. Dr. Apolo has served in national and international committees including the genitourinary track leader of the Education Program Committee and a member of the Scientific Program Committee of the American Society for Clinical Oncology (ASCO), a member of the Program Committee of the Society of Urologic Oncology (SUO), and chair of the Advocacy Network (BCAN) Think Tank Steering Committee.
Dr. Apolo is dedicated to improving the lives of patients with genitourinary tumors. Her research involves designing and implementing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is developing targeted and immune-based therapies in, including angiogenesis inhibitors and agents that target MET. Another research interest is improving detection of bladder tumors by developing new modalities. Finally, Dr. Apolo is interested in identifying molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies.
Click here for more information.